Mr. Speaker, in fact, since I did not have enough time to do so earlier, there is one thing I want to clarify: we have not yet made a decision to develop additional approval measures based on anticipated impact on the economy. However, I can assure the House that we are very aware of the concerns raised by the hon. member.
Canada has a strong biotechnology surveillance program. The Canadian biotechnology strategy includes a wide range of activities and initiatives, in particular, the identification of common issues, risk management and the implementation of measures to ensure public confidence in how Canada reacts to the challenges of biotechnology.
This approach to biotechnology has constantly evolved to respond to new scientific advances. Clearly, if a novel food ever presented a serious risk for our business practices, the appropriate action would be taken.
However, we are still just assessing the future impact. Until we know the outcome of discussions between Monsanto and stakeholders on the marketing of Roundup Ready wheat, there is no point in changing our current practices.